Transparency Market Research

Nanomedicine Market Is Expected to Reach USD 177.60 Billion Globally in 2019

Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019


Albany, NY -- (SBWIRE) -- 02/12/2014 -- According to a new market report published by Transparency Market Research “Nanomedicine Mark et (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) – Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019,“the market for nanomedicine was valued at USD 78.54 billion in 2012 and is expected to reach a value of USD 177.60 billion in 2019, growing at a CAGR of 12.3% from 2013 to 2019.

The advent of new applications and technology in the field of nanomedicine will be one of the major growth factors for the global Transparency Market Researchnanomedicine market. In addition, increase of funding aimed at boosting the research activities pertaining to nanomedicine by the government as well as private institutions will expedite the process of commercialization of new products and hence will drive the market. Other driving factors include rising base of geriatric population, presence of high unmet medical needs and rising worldwide incidences of chronic diseases.

The global nanomedicine market by applications was dominated by the oncology market with a market share of approximately 38.0% in 2012 on account of the presence of high number of commercialized products in this segment. Development of nanomedicine products enabling drugs crossing blood brain barrier and targeting the tumor in brain and at other sites in the body will prove to be a significant future growth driver for this market.

However, the global cardiovascular market for nanomedicine is the fastest growing application segment. Factors such as the presence of large patient prevalence coupled with rising demand for nanotechnology enabled drugs and devices catering to this segment, attribute to its high growth rate.

North America dominated the market in 2012 and is expected to maintain its market position till 2019. However, theAsia-Pacific market is estimated to grow at a faster pace (CAGR of 14.6% from 2013 to 2019).Europe is expected to grow at a relatively higher rate compared to North America owing to constantly improving regulatory framework and the presence of an extensive product pipeline portfolio.

Some of the key players in the global nanomedicine market include GE Healthcare, Merck & Co Inc., Abbott Laboratories, Pfizer Inc., Nanosphere Inc., Mallinckrodt plc, Teva Pharmaceutical Industries Ltd., Sigma-Tau Pharmaceuticals Inc., Celgene Corporation, Novavax, Inc.; Life Technologies, MagArray, Inc., Gilead Sciences Inc. and others.

Browse the full report with complete TOC at

The global nanomedicine market is categorized into the following segments:

Nanomedicine Market by Application

Nanomedicine Market by Geography
North America
Rest of the World (RoW)

Related Report
Hospital Acquired Disease Testing Market (Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

Nosocomial infections, most commonly called as hospital acquired diseases or healthcareassociated infections (HAI),are acquired by patients during their stay in hospitals. Since the last decade, remarkable prevalence of nosocomial infectionshas been observed worldwide and its morbidity rate is rapidly growing.Patients with weak immune system, those exposed to improper hygiene conditions in hospitals, the high neonatal population in developing countries and elderly patients worldwide are highly susceptibleto nosocomial infection. Aging of population is one of the major factors thathas increased the incidence rate of hospital acquired diseases worldwide. Growing morbidity rate has resulted in a rise in nosocomial infection mortality globally.

Contraction of nosocomial infection prolongs hospital stay of patients and ultimately the cost to the patientsas well as the hospital increases. Though various diagnostic tests are available in the market for detection of infectious microorganisms, approximately 70% of such pathogens are becoming resistant to at least one of the anti-bacterial drugs most commonly used in nosocomial infection treatments, thuscreating a challenge for healthcare professionals to treat such patients. Increasing resistance to commonly used antibiotics has created a demand for microorganism specific detection test for better assessment by healthcare professionals in order to provide appropriatetreatment. Molecular diagnostics, PCR, microarrays and solid phase hybridization are some of the major techniques used for the diagnosis of nosocomial infections. The development of nucleic acid testing (NAT) diagnostic products and related platforms have enabled the entry of many players in the hospital acquired disease testing market.

About Transparency Market Research
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453

Browse all Medical Devices Market Research Reports @